Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05894239
Title	A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Hoffmann-La Roche
Indications	Her2-receptor positive breast cancer
Therapies	Inavolisib + Pertuzumab/trastuzumab/hyaluronidase-zzxf Pertuzumab/trastuzumab/hyaluronidase-zzxf
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| POL \| ITA \| GBR \| FRA \| FIN \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG